论文部分内容阅读
目的对体外抗凝技术应用中凝血及并发症进行总结和分析。方法选取本院2014年1月至2016年12月使用体外抗凝技术的926例患者作为调查对象,所有患者采用微量泵泵入肝素体外抗凝方法解决终末期肾疾病活动性出血,分析了治疗中的出血原因及并发症,提出护理措施。结果对926例进行分析,其中发生凝血情况如下:2014年凝血2例;2015年凝血1例;2016年凝血1例。总结凝血原因有:血流量差、灌流器预冲不充分、肝素用量不精确。结论通过减少凝血及并发症的发生,体外抗凝技术可更广泛地应用于临床治疗,真正地为病人减轻痛苦。
Objective To summarize and analyze the coagulation and complications of anticoagulation in vitro. Methods A total of 926 patients using anticoagulation in vitro from January 2014 to December 2016 in our hospital were enrolled in this study. All patients received active anticoagulation with heparin in vitro to solve the active bleeding of end-stage renal disease. All patients were analyzed for treatment In the causes of bleeding and complications, proposed nursing measures. Results A total of 926 patients were analyzed. Among them, coagulation was as follows: 2 cases of coagulation in 2014, 1 case of coagulation in 2015 and 1 case of coagulation in 2016. Summary coagulation causes are: poor blood flow, perfusion preperfusion is not sufficient, the amount of heparin is not accurate. Conclusion By reducing the incidence of coagulation and complications, anticoagulation in vitro can be more widely used in clinical treatment, really reduce the pain for the patient.